Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Replimune Group, Inc.REPL · Entity 4707 | Director | May 16, 2024 | May 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Replimune Group, Inc.
Report date May 16, 2024 · Filed May 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,821,872 |
Reported balance
After 2024-05-16 transaction · row 1
1 source rowRow 1 · 2024-05-16 · Sale · Disposed 11,464 · Balance 1,821,872 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 20, 2024 20:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,464 | $6.47 | $74,172.08 |
DisclosureSEC source: 0001104659-24-063560 · tm2414961-3_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,821,872 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,861 | $18.05 | $141,891.05 |
DisclosureSEC source: 0001104659-23-062377 · tm2316199-8_3seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,833,336 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041718 · tm2311410-2_4seq1.xml · derivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041718 · tm2311410-2_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,841,197 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 16, 2022 Filed May 18, 2022 19:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,737 | $14.59 | $83,702.83 |
DisclosureSEC source: 0001104659-22-062606 · tm2215879d3_4seq.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,796,197 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 39,375 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042771 · tm2211665-2_4seq1.xml · derivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042771 · tm2211665-2_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,801,934 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,810 | $40.04 | $312,712.40 |
DisclosureSEC source: 0001104659-21-089919 · tm2121160-2_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775,684 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.13. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,775,684 shares of the Issuer's common stock. The reporting person also holds options to acquire 1,092,899 shares of the Issuer's common stock, 645,394 of which are exercisable as of the date hereof. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 22,826 | $40.05 | $914,181.30 |
DisclosureSEC source: 0001104659-21-087803 · tm2121160-1_4seq1.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,783,494 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,783,494 shares of the Issuer's common stock. The reporting person also holds options to acquire 1,092,899 shares of the Issuer's common stock, 635,306 of which are exercisable as of the date hereof. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,663 | $40.04 | $587,106.52 |
DisclosureSEC source: 0001104659-21-087803 · tm2121160-1_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806,320 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 115,300 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046729 · tm2112099-11_4seq1.xml · derivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,300 Underlying: Common Stock · 115,300 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 76,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046729 · tm2112099-11_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,820,983 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 29,803 | $43.99 | $1,311,033.97 |
DisclosureSEC source: 0001104659-21-007820 · tm213368d7_4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,744,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.41 to $44.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,744,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 483,771 of which are exercisable as of the date hereof. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 30,197 | $44.87 | $1,354,939.39 |
DisclosureSEC source: 0001104659-21-007820 · tm213368d7_4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773,921 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.38 to $45.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 220,000 | $40.04 | $8,808,800.00 |
DisclosureSEC source: 0001104659-20-139953 · tm2039457-2_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,804,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,804,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 468,928 of which are exercisable as of the date hereof. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $21.02 | $509,735.00 |
DisclosureSEC source: 0001104659-20-082857 · a4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,024,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,024,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 384,438 of which are exercisable as of the date hereof. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 145,500 | $22.32 | $3,247,560.00 |
DisclosureSEC source: 0001104659-20-082857 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048,368 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.8167 to $22.7299. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 16:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042499 · a4.xml · derivative · entry 1 Coffin Robert · CIK 0001376492 · Director · Pres & Chief Res & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 16:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.04 | $413,220.00 |
DisclosureSEC source: 0001104659-20-024250 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · Pres & Chief Res & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193,868 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,193,868 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 268,179 of which are exercisable as of the date hereof. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.03 | $412,977.50 |
DisclosureSEC source: 0001104659-20-021648 · a4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · Pres & Chief Res & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,218,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,218,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 264,534 of which are exercisable as of the date hereof. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.04 | $413,220.00 |
DisclosureSEC source: 0001104659-20-021648 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · Pres & Chief Res & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,242,368 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.00 | $412,250.00 |
DisclosureSEC source: 0001104659-19-061830 · a4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,266,618 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,266,618 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 233,709 of which are exercisable as of the date hereof. Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 21:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.02 | $412,735.00 |
DisclosureSEC source: 0001104659-19-061830 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,290,868 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 19:37 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.00 | $412,250.00 |
DisclosureSEC source: 0001104659-19-060673 · a4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,315,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 2,315,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 233,709 of which are exercisable as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 19:37 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.05 | $413,511.00 |
DisclosureSEC source: 0001104659-19-060673 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,339,368 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 16:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.00 | $412,250.00 |
DisclosureSEC source: 0001104659-19-059510 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,618 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 2,363,618 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 233,709 of which are exercisable as of the date hereof. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 16:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 24,250 | $17.05 | $413,462.50 |
DisclosureSEC source: 0001104659-19-051350 · a4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,387,868 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 2,387,868 shares of the Issuer's common stock. The reporting person also holds options to acquire 712,599 shares of the Issuer's common stock, 216,804 of which are exercisable as of the date hereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:22 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 219,300 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019706 · a4.xml · derivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,300 Underlying: Common Stock · 219,300 shares Expires 2029-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2020, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 17:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047447 · a4.xml · derivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President and C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-07-19 F1 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.